Thomas Fuller | SOPA Pictures | Lightrocket | Getty Pictures
Pfizer on Monday mentioned it might purchase weight reduction drugmaker Metsera in an as much as $7.3 billion deal, together with future funds, because it scrambles to win a slice within the booming weight problems drug market.
Pfizer mentioned it should pay an preliminary $47.50 a share in money for Metsera, an almost 43% premium to the biotech firm’s Friday’s closing value of $33.32. That provides the deal an enterprise worth of $4.9 billion.
The pact additionally features a contingent worth proper price as much as $22.50 a share based mostly on potential medical and regulatory achievements for Metsera’s medicines, which may carry the entire worth to $70 a share.
The deal is predicted to shut on the finish of the yr. Shares of Metsera rose greater than 60% in premarket buying and selling on Monday, whereas Pfizer’s inventory rose greater than 1%.
The transfer comes after a string of setbacks for Pfizer within the obseity house. The pharmaceutical big struggled to develop its personal lead weight problems drug candidate, danuglipron, earlier than deciding to scrap it totally in April attributable to security considerations. Pfizer additionally discontinued a special once-daily tablet in June 2023 attributable to elevated liver enzymes in sufferers who acquired it.
Pfizer has earlier-stage weight problems medicine in its pipeline that work in several methods, however the firm has confronted mounting investor strain to speed up its push into the market.
The chance could possibly be large. Some analysts anticipate the load loss drug house could possibly be price roughly $100 billion by the 2030s, with room for brand spanking new rivals to compete with well-liked injections from Eli Lilly and Novo Nordisk.
Metsera, based in 2022, brings a pipeline of each oral and injectable remedies with completely different targets that the corporate had picked up by means of its personal licensing and acquisition offers. That features a GLP-1 drug referred to as MET-233i, which helped sufferers lose as much as 8.4% of their weight in 36 days in a small, early-stage trial. Metsera is creating that remedy as a possible once-monthly injectable, which means that sufferers can take it much less incessantly than current weekly injections.
Metsera’s pipeline additionally features a month-to-month drug focusing on a hormone referred to as amylin, together with two oral GLP-1 candidates “anticipated to start trials imminently,” Pfizer mentioned in a launch.
“The proposed acquisition of Metsera aligns with our give attention to directing our investments to probably the most impactful alternatives and propels Pfizer into this key therapeutic space,” Pfizer CEO Albert Bourla mentioned in a press release. “We’re excited to use our deep cardiometabolic expertise and manufacturing and industrial infrastructure to speed up a portfolio that features potential best-in-class injectables.”
In a word on Monday, Leerink Companions analyst David Risinger mentioned the agency estimates Metsera’s weight problems candidates have the potential to generate greater than $5 billion in mixed peak annual gross sales. In a separate word on Monday, JPMorgan analyst Chris Schott mentioned Metsera’s experimental medicine “ought to speed up” Pfizer’s entry into the market.
The New York-based Metsera went public this yr in one of many greatest biotech listings of 2025. It’s amongst a number of corporations racing to develop next-generation weight problems remedies following the success of weekly injections comparable to Eli Lilly’s weight problems drug Zepbound and Novo Nordisk’s rival Wegovy.
